All In Biotech

Drug Trial Radar · NCT06438172

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

249

Actual

Start

Mar 25, 2024

Primary completion

Dec 2, 2024

Study completion Dec 2, 2024

Sponsor

Sponsor type
Industry
First posted
May 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension

Conditions

  • Hypertension

Interventions

  • HCP1803-3Drug

    Take it once daily for 8 weeks orally.

  • RLD2001-1Drug

    Take it once daily for 8 weeks orally.

  • HPP2003-3Drug

    Placebo drug. Take it once daily for 8 weeks orally.

  • HPP2002-1Drug

    Placebo drug. Take it once daily for 8 weeks orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in sitting systolic blood pressureTime frame: baseline, 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Donggguk University Ilsan Hospital

    Goyang-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.